Search
Avutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigational[A273948] Avutometinib was approved by the US FDA in May 2025 in a co-package alongside [defactinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian cancer … Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway.
Dicyclomine
go.drugbank.com/drugs/DB00804ApprovedInvestigationalDicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder
Zidebactam
go.drugbank.com/drugs/DB13090Approved[L63350,L63932] The combination is aimed at multidrug-resistant Gram-negative infections, a group for which treatment options are limited and where resistance to carbapenems has narrowed the available … [L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigational(mc-vc-PAB) that covalently attaches MMAE to polatuzumab. … Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells.
Fospropofol
go.drugbank.com/drugs/DB06716ApprovedIllicitInvestigationalWithdrawnFospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act. … Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent.
Mycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigational[A249175] This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. … it reaches the small intestine.
Synonyms: (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acidProducts: MICOFENOLATO DE MOFETILO, MICOFENOLATO DE MOFETILO CAPSULAS 250 MGCilnidipine
go.drugbank.com/drugs/DB09232InvestigationalCompared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium … This drug is approved in China, Japan, Korea, India, and several countries in the European Union.[A31970]
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB10990ApprovedThe vaccine contains Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]), which is a high molecular weight polymer prepared from the *Haemophilus influenzae* type b strain 20,752 … Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received
Synonyms: Haemophilus influenzae type B-PRP and tetanus toxoid conjugate (PRP-T)Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A7948] More than 99% of the drug compound is the R-enantiomer.[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.
Loracarbef
go.drugbank.com/drugs/DB00447ApprovedWithdrawnLoracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.